ERBB2 and non-small cell lung carcinoma: In a single-arm, open-label, phase II study, Poziotinib, an irreversible pan-HER inhibitor, showed hopeful antitumor activity with an ORR of 27% in patients with ERBB2 exon 20 mutant NSCLC including patients who had previously received platinum-based chemotherapy.